Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 Self-monitoring Blood Glucose Devices
5.1.1 By Component (Value and Volume, 2012-2025)
5.1.1.1 Glucometer Devices
5.1.1.2 Test Strips
5.1.1.3 Lancets
5.2 By Geography
5.2.1 Asia-Pacific (Value and Volume, 2012-2025)
5.2.1.1 Japan
5.2.1.1.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.2 South Korea
5.2.1.2.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.3 China
5.2.1.3.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.4 India
5.2.1.4.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.5 Australia
5.2.1.5.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.6 Vietnam
5.2.1.6.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.7 Malaysia
5.2.1.7.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.8 Indonesia
5.2.1.8.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.9 Philippines
5.2.1.9.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.10 Thailand
5.2.1.10.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.11 Rest of Asia-Pacific
5.2.1.11.1 By Component (Glucometer Device, Test Strips, Lancets)


6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2025)
6.2 Type 2 Diabetes Population (2012-2025)


7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Abbott
7.1.2 F. Hoffmann-La Roche AG
7.1.3 Johnson & Johnson
7.1.4 Arkray
7.1.5 Ascensia Diabetes Care
7.1.6 Agamatrix
7.1.7 Bionime Corporation
7.1.8 Acon
7.1.9 Medisana
7.1.10 Trivida
7.1.11 I-Sens
7.1.12 Morpen Laboratories
7.1.13 Rossmax International


8 MARKET OPPORTUNITIES AND FUTURE TRENDS